Published in Gene Therapy Weekly, December 12th, 2002
Erythropoietin (Epo) regulates the manufacture of red blood cells. Doctors often prescribe recombinant erythropoietin to accommodate its shortfall in chronically anemic patients. Now, a team at Oxford Biomedica has developed an oxygen-responsive erythropoietin gene therapy that corrects hemotocrit levels in research animals and which may be better than standard recombinant therapy.
They evaluated its efficacy in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.